Champions Oncology (CSBR) vs Rein Therapeutics (RNTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Champions Oncology (CSBR) has outperformed Rein Therapeutics (RNTX) over the past year, losing 23.0% versus a loss of 44.7%. Over five years, CSBR leads with a -50.6% price change compared with -96.2% for RNTX. Champions Oncology is the larger company by market cap ($69.3 million vs $67.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CSBR | RNTX |
|---|---|---|
| Share price | $4.98 | $0.7805 |
| Market cap | $69.31M | $67.33M |
| 1-day change | 0.00% | +1.46% |
| YTD return | -27.93% | -33.68% |
| 1-year return | -23.03% | -44.65% |
| 5-year return | -50.60% | -96.19% |
| Forward P/E | 49.80 | — |
| EPS (TTM) | $-0.07 | $-1.68 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.31 | $2.18 |
| 52-week low | $4.59 | $0.694 |
| Distance from 52-week high | -40.07% | -64.20% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +668.74% |
| Average volume | 11.33K | 430.81K |
| Shares outstanding | 13.92M | 86.27M |
| Employees | 214 | 10 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CSBR has outperformed RNTX by 21.6 percentage points over the past year.
About Champions Oncology
CSBR stock →Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice through TumorGraft Technology Platform.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 214 employees
About Rein Therapeutics
RNTX stock →Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
CSBR vs RNTX FAQ
Which is bigger, Champions Oncology or Rein Therapeutics?
Champions Oncology (CSBR) is larger, with a market capitalization of $69.31M compared with $67.33M for Rein Therapeutics (RNTX).
Which stock has performed better over the past year, CSBR or RNTX?
CSBR returned -23.03% over the past 12 months, compared with -44.65% for RNTX (price return, excluding dividends). Past performance does not predict future results.
Are Champions Oncology and Rein Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Champions Oncology and Biotechnology: Pharmaceutical Preparations for Rein Therapeutics.